摘要
目的观察参芪降糖颗粒联合胰岛素治疗2型糖尿病的临床疗效。方法选取2014年1月至2015年1月收治的2型糖尿病患者240例,随机分为观察组和对照组,各120例,两组患者均给予运动及饮食干预,同时根据情况应用控制血压及调节血脂药物。在此治疗基础上,对照组患者给予注射重组人胰岛素,观察组患者在对照组基础上联合参芪降糖颗粒,连续服用3个月后,比较两组患者的空腹血糖(FPG)、餐后2小时血糖(2h PG)、糖化血红蛋白(Hb A1 C)、胰岛β细胞功能(HOMA-β)的变化,并分别记录不良反应发生情况。结果治疗后,两组患者血糖参数(FPG,2h PG,Hb A1 C)均有下降,但观察组患者下降幅度明显大于对照组,差异有统计学意义(P<0.05);治疗后,对照组患者HOMA-β无明显变化,观察组患者HOMA-β则显著提高,组间比较,差异有统计学意义(P<0.05);治疗过程中,两组患者肝、肾功能均未出现异常,不良反应均较轻微。结论参芪降糖颗粒联合重组人胰岛素治疗2型糖尿病较单用重组人胰岛素治疗能更有效地控制血糖,改善并修复胰岛β细胞的功能,且安全性高,值得临床推广。
Objective To observe and explore the clinical efficacy of Shenqi Jiangtang Granules combined with insulin in the treatment of type 2 diabetes.Methods A total of 240 cases of patients with type 2 diabetes from January 2014 to January 2015 in the hospital were randomly divided into two groups,120 cases in each group.All patients were treated by exercise and diet intervention at the same time,with the application of blood pressure control and blood lipid drug according to the actual condition.The control group was treated with the injection of recombinant human insulin,and the observation group was added with Shenqi Jiangtang Granules on the basis of the control group.After 3 months of continuous medication,the changes of fasting plasma glucose（FPG）,postprandial 2 hour plasma glucose（2hPG）,glycosylated hemoglobin（HbA_（1C））,islet beta cell function（HOMA-β） were compared between the two groups,and the incidence rate of adverse reactions were recorded.Results After the treatment,the blood glucose parameters（FPG,2hPG,HbA_（1C）） in the two groups were decreased,but the observation group decreased more significantly than the control group（P〈0.05）.Compared with before treatment,the control group had no significant change in HOMA-β,while the observation group was significantly improved in HOMA-β（P〈0.05）.The liver and renal function of the two groups were not abnormal,the adverse reactions were mild,and the incidence rates of the two groups had no statistically significant difference.Conclusion Shenqi Jiangtang Granules combined with insulin can effectively control the blood glucose level and improve the efficacy of the patients with type 2 diabetes,and protect the function of pancreatic islet beta cells,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第22期95-96,F0003,共3页
China Pharmaceuticals
关键词
参芪降糖颗粒
重组人胰岛素
2型糖尿病
临床疗效
Shenqi Jiangtang Granules
recombinant human insulin
type 2 diabetes
clinical efficacy
